Sickle Cell Disease Gene Therapy on Hold After Adverse Events
Following 2 unexpected serious adverse events, the trial was put on clinical hold as of February 2021.
Intra-Articular FX201 Gene Therapy Shows Promise for Osteoarthritis
The therapy was generally well-tolerated and offered substantial pain relief in patients.
